Login

Amy Llopis Amenta

ORCID: 0009-0006-4922-9254
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
A5061557319
Research Areas
  • Receptor Mechanisms and Signaling
  • Lysosomal Storage Disorders Research
  • Biochemical and Molecular Research
  • Neuroscience and Neuropharmacology Research
  • Epilepsy research and treatment
  • Asthma and respiratory diseases
  • Mast cells and histamine
  • Virus-based gene therapy research

Invicro (United States)
 2019-2024

Konica Minolta (United States)
 2019

 Preclinical in vitro and in vivo evaluation of [11C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates
OPENALEX - Publications 
Isabel Piel Cristian Constantinescu David de la Puente Bethencourt David R. Bonsall Eugenii A. Rabiner and 6 more Kenneth Zasadny Amy Llopis Amenta Lisa Wells Thorsten Poethko Wolfgang Prange Martina Delbeck

This paper describes the preclinical validation of radioligand [

10.1177/0271678x241291949 article EN cc-by-nc Journal of Cerebral Blood Flow & Metabolism 2024-10-31
 Longitudinal imaging of therapeutic enzyme expression after gene therapy for Fabry disease using Positron Emission Tomography and the radiotracer [18F]AGAL
OPENALEX - Publications 
Charalambos Kaittanis Tyler J. Teceno Ashley C. Knight Yoann Petibon Phil Sandoval and 16 more Lawrence H. Cohen Shin Hye Ahn Anthony P. Belanger Louise Clark Quang-Dé Nguyen Wanida Ruangsiriluk Shreya Mukherji Cristian Constantinescu Amy Llopis Amenta Santhosshi Narayanan Mugdha Deshpande Rizwana Islam Shipeng Yuan Paul McQuade Christopher T. Winkelmann Talakad G. Lohith

10.1016/j.ymthe.2024.11.021 article EN cc-by Molecular Therapy 2024-11-01
 Imaging histamine H3 receptors with [18F]FMH3: Test–retest and occupancy studies in the non‐human primate
OPENALEX - Publications 
Christine M. Sandiego Olivier Barret Hsiaoju Lee David Alagille Amy Llopis Amenta and 4 more Krista Fowles Daniel Holden John Seibyl Gilles Tamagnan

Abstract A positron emission tomography (PET) radioligand, [ 18 F]FMH3, has been developed to interrogate histamine receptor subtype 3 (H3R), where dysfunction at this site is linked with obesity, sleep abnormality, and cognitive disorders. F]FMH3 was evaluated for imaging central H3R sites in non‐human primates through test–retest (TRT) dose‐receptor occupancy studies two selective antagonists order support clinical investigations. Two adult female baboons underwent PET brain scans the HR+,...

10.1002/syn.22096 article EN Synapse 2019-03-06
Coming Soon ...